3-Bromopropan-1-ol
Based on 1 Customer Validation
3-Bromopropan-1-ol is an endogenous metabolite. 3-Bromopropan-1-ol is significantly up-regulated during the estrous period of buffaloes. 3-Bromopropan-1-ol acts as an alkylating agent. 3-Bromopropan-1-ol participates in the enantioselective synthesis of nornicotine enantiomers. 3-Bromopropan-1-ol can be used in studies related to estrus detection in buffaloes.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.51%
- CAS No.: 627-18-9
- 화학식: C3H7BrO
- 분자량:138.99
-
보관:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Metabolism/Protease Compound Library
HY-L012
-
MCE Bioactive Compound Library
HY-L001V
-
Protein Kinase Compound Library
HY-L196
-
High-Throughput Bioactive Compound Library
HY-L205
-
Natural Product Diversity Scaffold Library
HY-L245
All Endogenous Metabolite Isoforms
More
Biological Activity
3-Bromopropan-1-ol serves as an alkylating reagent in the asymmetric synthesis of nornicotine precursors[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 627-18-9
-
Appearance Liquid (Density: 1.537 g/cm3)
-
분자량 138.99
-
화학식 C3H7BrO
-
Color Colorless to light yellow
-
SMILES
OCCCBr
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
용액&용해도
DMSO : ≥ 200 mg/mL (1438.95 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (35.97 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (35.97 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
순도&문서
-
Data Sheet (268 KB)
-
SDS (554 KB)
- English - EN (554 KB)
- Français - FR (554 KB)
- Deutsch - DE (554 KB)
- Norwegian - NO (554 KB)
- Español - ES (554 KB)
- Swedish - SV (554 KB)
- Italian - IT (554 KB)
- Korean - KR (554 KB)
- Portuguese - PT (554 KB)
-
Handling Instructions (2659 KB)
References
[1]. Chojnacki K, et al. Synthesis of Novel Acyl Derivatives of 3-(4,5,6,7-Tetrabromo-1H-benzimidazol-1-yl)propan-1-ols-Intracellular TBBi-Based CK2 Inhibitors with Proapoptotic Properties. Int J Mol Sci. 2021 Jun 10;22(12):6261. [Content Brief]
[2]. Swango JH, et al. A novel enantioselective synthesis of (S)-(-)- and (R)-(+)-nornicotine via alkylation of a chiral 2-hydroxy-3-pinanone ketimine template. Chirality. 1999;11(4):316-318. [Content Brief]
[3]. Doshi P, et al. Untargeted metabolomics of buffalo urine reveals hydracyrlic acid, 3-bromo-1-propanol and benzyl serine as potential estrus biomarkers. J Proteomics. 2024;296:105124. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 7.1948 mL | 35.9738 mL | 71.9476 mL | 179.8690 mL |
| 5 mM | 1.4390 mL | 7.1948 mL | 14.3895 mL | 35.9738 mL | |
| 10 mM | 0.7195 mL | 3.5974 mL | 7.1948 mL | 17.9869 mL | |
| 15 mM | 0.4797 mL | 2.3983 mL | 4.7965 mL | 11.9913 mL | |
| 20 mM | 0.3597 mL | 1.7987 mL | 3.5974 mL | 8.9935 mL | |
| 25 mM | 0.2878 mL | 1.4390 mL | 2.8779 mL | 7.1948 mL | |
| 30 mM | 0.2398 mL | 1.1991 mL | 2.3983 mL | 5.9956 mL | |
| 40 mM | 0.1799 mL | 0.8993 mL | 1.7987 mL | 4.4967 mL | |
| 50 mM | 0.1439 mL | 0.7195 mL | 1.4390 mL | 3.5974 mL | |
| 60 mM | 0.1199 mL | 0.5996 mL | 1.1991 mL | 2.9978 mL | |
| 80 mM | 0.0899 mL | 0.4497 mL | 0.8993 mL | 2.2484 mL | |
| 100 mM | 0.0719 mL | 0.3597 mL | 0.7195 mL | 1.7987 mL |
3-Bromopropan-1-ol Related Classifications
HY-W007337 Related Classifications
Powered by Bioz